{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:21Z","timestamp":1787026821545,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014383","name":"Italfarmaco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>No treatments are approved for Becker muscular dystrophy (BMD). This study investigated the efficacy and safety of givinostat, a histone deacetylase pan-inhibitor, in adults with BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Males aged 18\u201365 years with a diagnosis of BMD confirmed by genetic testing were randomized 2:1 to 12 months treatment with givinostat or placebo. The primary objective was to demonstrate statistical superiority of givinostat over placebo for mean change from baseline in total fibrosis after 12 months. Secondary efficacy endpoints included other histological parameters, magnetic resonance imaging and spectroscopy (MRI and MRS) measures, and functional evaluations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 51 patients enrolled, 44 completed treatment. At baseline, there was greater disease involvement in the placebo group than givinostat, based on total fibrosis (mean 30.8 vs. 22.8%) and functional endpoints. Mean total fibrosis did not change from baseline in either group, and the two groups did not differ at Month 12 (least squares mean [LSM] difference 1.04%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.8282). Secondary histology parameters, MRS, and functional evaluations were consistent with the primary. MRI fat fraction in whole thigh and quadriceps did not change from baseline in the givinostat group, but values increased with placebo, with LSM givinostat\u2013placebo differences at Month 12 of \u22121.35% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0149) and \u22121.96% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0022), respectively. Adverse events, most mild or moderate, were reported by 88.2% and 52.9% patients receiving givinostat and placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study failed to achieve the primary endpoint. However, there was a potential signal from the MRI assessments suggesting givinostat could prevent (or slow down) BMD disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2023.1095121","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:18:48Z","timestamp":1675052328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study"],"prefix":"10.3389","volume":"14","author":[{"given":"Giacomo P.","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Vandenborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Cinnante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermien E.","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Velardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ripolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules J.","family":"van Benthem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke M.","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ambrosoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo U.","family":"Bettica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","article-title":"Improved diagnosis of becker muscular dystrophy by dystrophin testing","volume":"39","author":"Clarke","year":"1989","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1177\/0192623317734823","article-title":"Duchenne and Becker muscular dystrophies: a review of animal models, clinical end points, and biomarker quantification","volume":"45","author":"Wilson","year":"2017","journal-title":"Toxicol Pathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-022-01354-3","article-title":"Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy","volume":"10","author":"Ripolone","year":"2022","journal-title":"Acta Neuropathol Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pmr.2011.11.014","article-title":"The paradox of muscle hypertrophy in muscular dystrophy","volume":"23","author":"Kornegay","year":"2012","journal-title":"Phys Med Rehabil Clin N Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jns.2014.10.030","article-title":"Calf muscle involvement in Becker muscular dystrophy: when size does not matter","volume":"347","author":"Monforte","year":"2014","journal-title":"J Neurol Sci."},{"key":"B6","unstructured":"Dystrophinopathies\n            DarrasBT\n            UrionDK\n            GhoshPS\n          \n            AdamMP\n            ArdingerHH\n            PagonRA\n            WallaceSE\n            BeanLJ\n            StephensK\n            AmemiyaA\n          Seattle, WAUniversity of WashingtonGeneReviews2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41439-019-0083-5","article-title":"Becker muscular dystrophy caused by exon 2-truncating mutation of DMD","volume":"6","author":"Ikeda","year":"2019","journal-title":"Hum Genome Var."},{"key":"B8","doi-asserted-by":"publisher","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations","volume":"42","author":"McDonald","year":"2010","journal-title":"Muscle Nerve."},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure scale for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscul Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.nmd.2016.04.009","article-title":"The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: a cross-sectional study","volume":"26","author":"Fischer","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1469-8749.2009.03316.x","article-title":"Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure","volume":"52","author":"Vuillerot","year":"2010","journal-title":"Dev Med Child Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/mus.27475","article-title":"Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments","volume":"65","author":"Comi","year":"2022","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skelet Muscle."},{"key":"B17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"16060","DOI":"10.1038\/s41598-017-16170-2","article-title":"Muscle MRI and functional outcome measures in Becker muscular dystrophy","volume":"7","author":"Barp","year":"2017","journal-title":"Sci Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/mus.24246","article-title":"Magnetic resonance imaging phenotyping of Becker muscular dystrophy","volume":"50","author":"Faridian-Aragh","year":"2014","journal-title":"Muscle and Nerve."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e513","DOI":"10.1212\/WNL.0000000000012233","article-title":"Selection approach to identify the optimal biomarker using quantitative muscle MRI and functional assessments in Becker muscular dystrophy","volume":"97","author":"van de Velde","year":"2021","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"613489","DOI":"10.3389\/fneur.2020.613489","article-title":"Quantitative muscle MRI as outcome measure in patients with Becker muscular dystrophy - a 1-year follow-up study","volume":"11","author":"Sheikh","year":"2021","journal-title":"Front Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e4691","DOI":"10.1002\/nbm.4691","article-title":"Baseline fat fraction is a strong predictor of disease progression in Becker muscular dystrophy","volume":"35","author":"Veeger","year":"2022","journal-title":"NMR Biomed."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.nmd.2012.05.015","article-title":"Muscle MRI in Becker muscular dystrophy","volume":"22","author":"Tasca","year":"2012","journal-title":"Neuromuscul Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e4385","DOI":"10.1002\/nbm.4385","article-title":"Multi-parametric MR in Becker muscular dystrophy patients","volume":"33","author":"Hooijmans","year":"2020","journal-title":"NMR Biomed."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/nbm.3199","article-title":"Muscle MRS detects elevated PDE\/ATP ratios prior to fatty infiltration in Becker muscular dystrophy","volume":"27","author":"Wokke","year":"2014","journal-title":"NMR Biomed."},{"key":"B27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","article-title":"Dystrophin levels and clinical severity in Becker muscular dystrophy patients","volume":"85","author":"Van Den Bergen","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/ana.24743","article-title":"Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I","volume":"80","author":"L\u00f8kken","year":"2016","journal-title":"Ann Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1148\/radiol.14141191","article-title":"Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2* changes","volume":"275","author":"Loughran","year":"2015","journal-title":"Radiology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/mrm.25072","article-title":"Investigating the quantitative fidelity of prospectively undersampled chemical shift imaging in muscular dystrophy with compressed sensing and parallel imaging reconstruction","volume":"72","author":"Hollingsworth","year":"2014","journal-title":"Magn Reson Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/mus.24629","article-title":"Longitudinal 2-point dixon muscle magnetic resonance imaging in Becker muscular dystrophy","volume":"51","author":"Bonati","year":"2015","journal-title":"Muscle Nerve."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1212\/WNL.0000000000009244","article-title":"Modeling disease trajectory in Duchenne muscular dystrophy","volume":"94","author":"Rooney","year":"2020","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1212\/WNL.0000000000008939","article-title":"MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy","volume":"94","author":"Naarding","year":"2020","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1737","DOI":"10.1212\/WNL.0000000000012724","article-title":"Association of elbow flexor MRI fat fraction with loss of hand-to-mouth movement in patients with Duchenne muscular dystrophy","volume":"97","author":"Naarding","year":"2021","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","article-title":"MR biomarkers predict clinical function in Duchenne muscular dystrophy","volume":"94","author":"Barnard","year":"2020","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.V130.Suppl_1.253.253","article-title":"A two-part study of givinostat in patients with polycythemia vera: the maximum tolerated dose selection and the proof of concept final results","volume":"130","author":"Rambaldi","year":"2017","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JND-140005","article-title":"Forty-five years of Duchenne muscular dystrophy in the Netherlands","volume":"1","author":"van den Bergen","year":"2014","journal-title":"J Neuromuscul Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1095121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:18:52Z","timestamp":1675052332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1095121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":39,"alternative-id":["10.3389\/fneur.2023.1095121"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1095121","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"article-number":"1095121"}}